# A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment

> **NCT07708181** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Gout Arthritis

## Interventions

- **DRUG:** SSGJ-613 100 mg Q12W
- **DRUG:** SSGJ-613 200 mg Q12W
- **DRUG:** SSGJ-613 100 mg Q4W
- **DRUG:** Colchicine 0.5 mg

## Key facts

- **NCT ID:** NCT07708181
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-02
- **Primary completion:** 2027-08-11
- **Final completion:** 2028-04-19
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708181, "A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07708181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*